Levonorgestrel intrauterine system for endometrial protection

Journal of the British Menopause Society

Volumn 12, Issue SUUPL. 1, 2006, Pages 1-3

  Sturdee, David ^a  

^a SOLIHULL HOSPITAL   (United Kingdom)

Author keywords

Endometrial protection; Hormone replacement; Intrauterine system; Levonorgestrel; Menopause

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PLACEBO;

BREAST CANCER; CLIMACTERIUM; CLINICAL TRIAL; CONTRACEPTION; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MENORRHAGIA; PREMENSTRUAL SYNDROME; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VAGINA BLEEDING; WITHDRAWAL BLEEDING;

ADULT; ENDOMETRIAL HYPERPLASIA; FEMALE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENOPAUSE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33644811197     PISSN: 13621807     EISSN: 13621807     Source Type: Journal    
DOI: 10.1258/136218006775992176     Document Type: Review

References (11)

1. Voigt LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7
2. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7
3. Sturdee D.W, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG 2000;107:1392-400
4. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48
5. Schering Health Care. Mirena Summary of Product Characteristics. September 2004
6. Zhu P, Liu X, Luo H, et al. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Hum Reprod 1999;14:970-5
7. Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76: 969-73
8. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000;3:199-211
9. Raudaskoski T, Tapanainen J, Tomás E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136-44
10. Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-19
11. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813-17